Format

Send to

Choose Destination
Radiother Oncol. 2017 Sep;124(3):357-364. doi: 10.1016/j.radonc.2017.07.004. Epub 2017 Jul 20.

Utilizing circulating tumour DNA in radiation oncology.

Author information

1
Princess Margaret Cancer Center, University Health Network, Toronto, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Canada.
2
Princess Margaret Cancer Center, University Health Network, Toronto, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Canada. Electronic address: scott.bratman@rmp.uhn.ca.

Abstract

Emerging technologies for detection of circulating tumour DNA (ctDNA) are expanding the possibilities for clinical impact to patients with localized, potentially curable cancer. For such patients, ctDNA analysis could aid in prognostication, prediction of treatment response, longitudinal monitoring for adaptive treatment, and evaluation of minimal residual disease. Radiation oncologists currently have few tools at their disposal for predicting or rapidly assessing treatment efficacy. By reflecting the genetic and epigenetic makeup of tumours as well as dynamic changes with treatment, ctDNA as a biomarker for radiation response could enable new personalized treatment approaches. In this review, we will discuss recent advances in ctDNA technologies and potential clinical applications of ctDNA analysis throughout the therapeutic course. Furthermore, we will consider how ctDNA analysis could someday guide radiotherapy prescriptions by revealing differences in tumour radiophenotype.

KEYWORDS:

Cell-free DNA; Circulating tumour DNA; Liquid biopsy; Personalized medicine; Precision radiation medicine

PMID:
28735685
DOI:
10.1016/j.radonc.2017.07.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center